Universal CAR-T: End-to-End Safety Assessment Solution
Universal CAR-T
End-to-End Safety Assessment
From Target to IND in One Solution
While gene editing enables transformative therapies, it introduces novel safety risks including off-target effects, chromosomal structural variations, and vector integration. GeneRulor integrates 7 core technology platforms to deliver standardized safety assessment covering the entire workflow from target design to IND submission, helping you pass regulatory review on the first try.
Regulatory Evolution: Gene Editing Safety is Now the Core IND Barrier
Universal CAR-T achieves "off-the-shelf" availability by knocking out TCR and HLA genes, but multi-gene editing introduces safety risks that have become the focus of global regulators. The 2024 FDA guidance explicitly requires comprehensive genomic safety assessment using multiple complementary methods.
CDE/FDA Guideline Evolution Timeline
Three Core Challenges Across the UCAR-T Lifecycle
From target screening to IND submission, companies universally face technical complexity, vendor fragmentation, and extended timelines. Any misstep can lead to regulatory rejection.
Phased End-to-End Safety Assessment Roadmap
Following the "phased, multi-dimensional" principle, we progress from upstream editing tool optimization to final comprehensive validation, ensuring data reliability and regulatory compliance.
Phase 1: Target Optimization & Screening
CRISPRme prediction → GUIDE-seq Pool detection → flow cytometry screening → amplicon validation to select high-fidelity sgRNAs
Phase 2: IND-Level Safety Assessment
Off-target effect analysis → chromosomal structural stability → vector integration detection → editing tool residuals to form core data package
Phase 3: Data Integration & Submission
Comprehensive safety dossier compilation, submission support and expert consultation to ensure first-pass approval
Seven Core Service Modules
Covers all technical requirements for UCAR-T products from target design to IND submission, with each module aligned to the latest regulatory guidelines.
sgRNA Target Optimization & Screening
Systematically screen for high-quality sgRNAs combining high on-target efficiency and low off-target risk, laying the foundation for subsequent development.
- CRISPRme genome-wide off-target prediction
- GUIDE-seq Pool high-throughput screening
- Flow cytometry editing efficiency validation
- Amplicon sequencing off-target quantification
- QC: Cumulative off-target ≤10%, single site ≤5%
Editing Tools & Delivery Systems
Diverse selection of editing tools and delivery options to match different cell types and development stages.
- SpCas9/eSpCas9/HiFi Cas9 variants
- RNP Electroporation no DNA residue, clinical preferred
- Lentivirus / IDLV delivery
- Customized LvNP nanoparticle delivery
Editing Efficacy Validation
Multi-level validation of gene editing success to ensure on-target editing meets expectations.
- T7E1 endonuclease preliminary screening
- Sanger sequencing editing pattern analysis
- NGS Amplicon Deep Sequencing (LOD 0.01%)
- Flow cytometry functional phenotype validation
Comprehensive Off-Target Analysis
Core IND data package using orthogonal "in vivo + in vitro + in silico" strategy to build complete evidence chain.
- GUIDE-seq gold standard cellular off-target assay
- AID-seq high-sensitivity in vitro off-target detection
- CRISPRme prediction and risk ranking
- Solution-phase hybrid capture validation
- Multi-donor validation for low-frequency events
Chromosomal Structural Stability
Comprehensive detection of chromosomal structural variations caused by gene editing to eliminate major safety risks.
- PEM-seq high-sensitivity translocation detection
- Long-range PCR large deletion detection
- G-banding karyotyping
- Multi-scale coverage: bp → kb → Mb
Vector Integration Site Analysis
Precise analysis of vector integration sites, copy numbers and potential oncogenic risks in the genome.
- LM-PCR for lentivirus/transposon integration
- Solution-phase hybrid capture for rare AAV integration
- Single-base resolution integration mapping
- Clonal tracking and genotoxicity assessment
- Detection limit: 0.01%
Editing Tool Residue Detection
High-sensitivity detection of editing tool residuals in final products to meet lot release QC requirements.
- RT-qPCR sgRNA residue detection (pg level)
- Double-antibody Sandwich ELISA Cas9 protein detection
- ICH Q2(R1) validation compliant
- Supports batch release testing
Flexible Service Options
Customized solutions based on your development stage and specific needs to maximize project efficiency.
IND Safety Assessment Package
Ideal for clients preparing for IND filing, one-stop delivery of complete regulatory-compliant safety data.
Full-Process Custom Service
End-to-end support from target design to IND submission for early-stage R&D clients.
Individual Technical Services
Select individual services as needed for clients with specific testing requirements.
Why Choose GeneRulor One-Stop Solution
Compared to traditional multi-vendor models, we significantly reduce project timelines, lower management costs, and improve submission success rates.
Our Core Advantages
Deep expertise in gene editing safety assessment with full-chain technical capabilities and proven IND submission experience.
Preparing Your UCAR-T IND Submission? Get a Custom Assessment Plan
Tell us your product type and development stage, and we will provide a customized genomic safety assessment plan and timeline compliant with FDA/CDE requirements.
![Micromessenger Scan to consult](javascript:Site.hoverQrCode("//33974620.s21i.faiusr.com/2/ABUIABACGAAg9by4zQYo7oak_wUwxwY40QY.jpg",this,{"tips":"请使用微信扫一扫"});){kind=link}
![Linkedin LIN HUABING](javascript:Site.hoverQrCode("//33974620.s21i.faiusr.com/4/ABUIABAEGAAgloWpzgYo0eeGgAUwhgQ4igQ.png",this,{"tips":"Scan QR code"});){kind=link}